These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6278852)

  • 1. Differences in the plasma kinetics of daunorubicin in normal and leukemic rats.
    Andersson B; Beran M; Alván G; Peterson C
    Acta Radiol Oncol; 1981; 20(5):325-8. PubMed ID: 6278852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.
    Nooter K; Sonneveld P; Martens A
    Cancer Res; 1985 Sep; 45(9):4020-5. PubMed ID: 4027999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
    Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
    Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia.
    DeGregorio MW; Carrera CJ; Klock JC; Pegelow CH; Wilbur JR
    Cancer Treat Rep; 1982 Dec; 66(12):2085-8. PubMed ID: 6958366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
    Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
    Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.
    Hulhoven R
    Biomedicine; 1978 Jul; 29(5):164-7. PubMed ID: 719130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.
    Gessner T; Preisler HD; Azarnia N; Bolanowska W; Vogler WR; Grunwald H; Joyce R; Goldberg J
    Med Oncol Tumor Pharmacother; 1987; 4(1):23-31. PubMed ID: 3600054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
    Paul C; Tidefelt U; Liliemark J; Peterson C
    Leuk Res; 1989; 13(2):191-6. PubMed ID: 2927175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.
    Andersson B; Andersson I; Beran M; Ehrsson H; Eksborg S
    Cancer Chemother Pharmacol; 1979; 2(1):15-7. PubMed ID: 498413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
    Eksborg S; Björkholm M; Hast R; Fagerlund E
    Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
    Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
    Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.
    Andersson B; Beran M
    Cancer Chemother Pharmacol; 1980; 4(3):205-7. PubMed ID: 7397945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.
    Nilsson SO; Andersson B; Eksborg S; Beran M; Ehrsson H
    Cancer Chemother Pharmacol; 1981; 5(4):261-6. PubMed ID: 7261253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
    Krogh-Madsen M; Bender B; Jensen MK; Nielsen OJ; Friberg LE; Honoré PH
    Cancer Chemother Pharmacol; 2012 May; 69(5):1155-63. PubMed ID: 22212298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disposition of 5-iminodaunorubicin in the rat.
    Peters JH; Gordon GR; Kashiwase D; Acton EM
    Cancer Res; 1984 Apr; 44(4):1453-9. PubMed ID: 6704961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of liposomal daunorubicin in children.
    Hempel G; Reinhardt D; Creutzig U; Boos J
    Br J Clin Pharmacol; 2003 Oct; 56(4):370-7. PubMed ID: 12968981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
    Eksborg S; Ehrsson H; Andersson B; Beran M
    J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.